13R FATE
Expecting a 13R move here.
Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical-stage biotechnology company specializing in induced pluripotent stem cell (iPSC) technology to develop cellular immunotherapies for cancer and immune disorders. Below are its key fundamentals:
Financial Overview:
Revenue: 3.1M in Q3 2024, primarily from preclinical development collaborations.
Net Loss: 134M in the first three quarters of 2024, reflecting high R&D and administrative expenses.
Cash Position: 297M as of September 2024, with no debt and a cash runway of 2.2 years.
Operating Expenses: 55.5M in Q3 2024, including 34.7M for R&D and 20.8M for general administration.
Key Metrics:
Market Cap: Approximately 191M
Debt-to-Equity Ratio: 0%, indicating no leverage.
Cash Per Share: $5.86, making it an attractive takeover target.
Institutional Ownership: Over 98% of shares.
Challenges:
Declining Revenue: Revenue dropped significantly year-over-year due to reduced collaboration income.
High Cash Burn: Burn rate of 133M annually, though reduced by 28% compared to the previous year.
Speculative Risks: High volatility and likelihood of financial distress within two years.
Outlook:
Fate Therapeutics is focused on advancing its iPSC-based pipeline but faces financial pressure due to declining revenue and ongoing losses. Its strong cash position provides a temporary cushion, but long-term viability depends on successful clinical progress and partnerships.
Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical-stage biotechnology company specializing in induced pluripotent stem cell (iPSC) technology to develop cellular immunotherapies for cancer and immune disorders. Below are its key fundamentals:
Financial Overview:
Revenue: 3.1M in Q3 2024, primarily from preclinical development collaborations.
Net Loss: 134M in the first three quarters of 2024, reflecting high R&D and administrative expenses.
Cash Position: 297M as of September 2024, with no debt and a cash runway of 2.2 years.
Operating Expenses: 55.5M in Q3 2024, including 34.7M for R&D and 20.8M for general administration.
Key Metrics:
Market Cap: Approximately 191M
Debt-to-Equity Ratio: 0%, indicating no leverage.
Cash Per Share: $5.86, making it an attractive takeover target.
Institutional Ownership: Over 98% of shares.
Challenges:
Declining Revenue: Revenue dropped significantly year-over-year due to reduced collaboration income.
High Cash Burn: Burn rate of 133M annually, though reduced by 28% compared to the previous year.
Speculative Risks: High volatility and likelihood of financial distress within two years.
Outlook:
Fate Therapeutics is focused on advancing its iPSC-based pipeline but faces financial pressure due to declining revenue and ongoing losses. Its strong cash position provides a temporary cushion, but long-term viability depends on successful clinical progress and partnerships.
כתב ויתור
המידע והפרסומים אינם אמורים להיות, ואינם מהווים, עצות פיננסיות, השקעות, מסחר או סוגים אחרים של עצות או המלצות שסופקו או מאושרים על ידי TradingView. קרא עוד בתנאים וההגבלות.
כתב ויתור
המידע והפרסומים אינם אמורים להיות, ואינם מהווים, עצות פיננסיות, השקעות, מסחר או סוגים אחרים של עצות או המלצות שסופקו או מאושרים על ידי TradingView. קרא עוד בתנאים וההגבלות.